Key Points
- Director Luke Evnin sold 316,463 shares of Werewolf Therapeutics between December 3 and December 17, bringing in roughly $319,090, and after the latest sale still directly owns 2,841,957 shares (a 0.35% reduction from that transaction).
- HOWL shares traded as low as $0.60 on the latest session; the company is a small-cap biopharma (~$29.2M market cap) with negative EPS, while analysts hold a "Moderate Buy" consensus and a $7.75 average price target.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 9,983 shares of the firm's stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $1.14, for a total value of $11,380.62. Following the sale, the director directly owned 2,841,957 shares in the company, valued at approximately $3,239,830.98. This trade represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Luke Evnin also recently made the following trade(s):
- On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.05, for a total value of $15,275.40.
- On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $25,294.80.
- On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total transaction of $19,286.64.
- On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63.
- On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total transaction of $39,330.24.
- On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total value of $45,015.70.
- On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $33,700.59.
- On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $16,070.96.
- On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
- On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total value of $31,951.62.
Werewolf Therapeutics Price Performance
Shares of HOWL stock traded down $0.47 during trading hours on Thursday, hitting $0.60. 3,193,548 shares of the company's stock were exchanged, compared to its average volume of 508,030. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $2.38. The firm has a market cap of $29.17 million, a P/E ratio of -0.36 and a beta of 0.74. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The firm has a 50 day moving average of $1.22 and a two-hundred day moving average of $1.32.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. Sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.
Hedge Funds Weigh In On Werewolf Therapeutics
Several large investors have recently modified their holdings of HOWL. Charles Schwab Investment Management Inc. increased its position in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock worth $93,000 after purchasing an additional 23,852 shares during the last quarter. Nuveen LLC acquired a new position in Werewolf Therapeutics in the first quarter valued at about $71,000. MPM Asset Management LLC boosted its stake in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after buying an additional 25,688 shares during the period. MPM Bioimpact LLC increased its position in shares of Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after acquiring an additional 20,799 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at approximately $79,000. Institutional investors and hedge funds own 64.84% of the company's stock.
Wall Street Analysts Forecast Growth
HOWL has been the subject of several research analyst reports. Citigroup restated a "market outperform" rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. JMP Securities reduced their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a report on Thursday, August 21st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Zacks Research downgraded Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 21st. Finally, Bank of America decreased their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.75.
View Our Latest Report on Werewolf Therapeutics
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
